KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Role of NK cells in cord blood transplantation and their enhancement by the missing ligand effect of the killer-immunoglobulin like receptor.Frontiers in genetics · 2022
   Review
2. Use of the HLA-B leader to optimize cord blood transplantationHaematologica · 2021
   Article
3. Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients.Cancers · 2021
   Review
4. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy.Cancers · 2019
   Review
5. NK cell therapy for hematologic malignancies.International journal of hematology · 2018
   Review
6. Importance of conditioning regimen intensity, MRD positivity, and KIR ligand mismatch in UCB transplantation.Bone marrow transplantation · 2018
   Article
7. Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
   Review
8. Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.Frontiers in immunology · 2017
   Article
9. Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications.Frontiers in immunology · 2017
   Review
10. Can we make a better match or mismatch with KIR genotyping?Hematology. American Society of Hematology. Education Program · 2016
    Review
11. Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).Bone marrow transplantation · 2016
    Article
12. Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Article
13. Cord Blood as a Source of Natural Killer Cells.Frontiers in medicine · 2015
    Review
14. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission.Blood cancer journal · 2013
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as